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Abstract
The human ABCG2 multidrug transporter plays a crucial role in the absorption and excretion of xeno- and endobiotics; thus 
the relatively frequent polymorphic and mutant ABCG2 variants in the population may significantly alter disease conditions 
and pharmacological effects. Low-level or non-functional ABCG2 expression may increase individual drug toxicity, reduce 
cancer drug resistance, and result in hyperuricemia and gout. In the present work we have studied the cellular expression, 
trafficking, and function of nine naturally occurring polymorphic and mutant variants of ABCG2. A comprehensive analysis 
of the membrane localization, transport, and ATPase activity, as well as retention and degradation in intracellular compart-
ments was performed. Among the examined variants, R147W and R383C showed expression and/or protein folding defects, 
indicating that they could indeed contribute to ABCG2 functional deficiency. These studies and the applied methods should 
significantly promote the exploration of the medical effects of these personal variants, promote potential therapies, and help 
to elucidate the specific role of the affected regions in the folding and function of the ABCG2 protein.
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Introduction
The human ABCG2 belongs to the ABC superfamily and is 
responsible for the transfer of wide variety of endogenous 
substances through the plasma membrane [1, 2]. ABCG2 is 
present in the GI tract [3, 4], the blood–brain barrier [5], the 
placenta [6], and in various stem cells [7]. This transporter 
protein is very important for the absorption, distribution, 
metabolism, and excretion of various pharmacological 
agents and the severity of their potential toxicity (ADME-
Tox parameters, [8]). In addition to its crucial defense role in 
normal tissues, ABCG2 is also involved in multidrug resist-
ance in cancer cells [9, 10].
There is growing evidence that the reduced level and/or 
function of ABCG2 contribute to the development of the 
painful disease, gout. Recent studies suggest that ABCG2 
dysfunction causes a decrease in the uric acid excretion, 
especially in the intestine, resulting in hyperuricemia 
[11]. Genome-wide association studies (GWAS) revealed 
that one of the common single nucleotide polymorphisms 
(SNP), ABCG2-Q141K, is strongly associated with higher 
serum urate levels [12, 13] and gout [14–17]. It has also been 
established that numerous missense mutations in the ABCG2 
gene are also present in the human population [18–20], and 
some of these mutations may lead to reduced function and/
or expression of the protein.
In our recent work, we found a new missense variant, 
ABCG2-M71V, which resulted in about 50% reduction in 
the expression of the ABCG2 protein in the erythrocyte 
membrane of heterozygous carriers [21]. This mutation 
was found to be relatively frequent in a heterozygous form 
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(about 1%) in Europe, and we could demonstrate a major 
effect of this mutation on the expression and function of the 
ABCG2 protein. According to SNP databases (e.g. NCBI 
SNP database), several hundred other missense mutations 
may be present in the ABCG2 gene in the general human 
population, while the molecular and cellular effects of most 
of these mutations are currently unexplored.
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In 2017, several ABCG2 gene mutations were found in 
Europe in a cohort of gout patients [22], and while the pre-
sent manuscript was under review, the same group published 
a further analysis of these variants in clinical samples and 
performed experiments to assess the expression and function 
of these variants [23]. In the present work we have performed 
a comprehensive analysis of the expression, localization, and 
activity of the naturally occurring M71V, R147W, T153M, 
K360Δ, F373C, R383C, T434M, and S476P ABCG2 vari-
ants and compared their effects to the wild-type protein, as 
well as to the widely present (about 20% of heterozygotes 
in Europe) ABCG2-Q141K polymorphism, reducing both 
expression and function of ABCG2 [24–27]. For large-scale 
rapid screening of missense ABCG2 variants we present 
here an efficient transient expression system, while a detailed 
cellular localization and processing study was performed 
using stable cellular ABCG2 expression. Our cellular stud-
ies, along with the recently published atomic level model of 
the ABCG2 protein [28], appoint those regions which are 
essential for the proper folding, trafficking and functioning 
of this protein.
Results
Transient expression of the ABCG2 variants 
in human cell lines
In order to explore the effects of nine naturally occurring 
ABCG2 variants in human model cells, we performed a tran-
sient expression of these proteins in HEK cells. To ensure 
controlled, uniform transfection levels, we have generated 
plasmids which contained the cDNA of ABCG2 and EGFP 
separated by an IRES sequence. Using these constructs, the 
successfully transfected cells could be separated by flow 
cytometry, based on EGFP fluorescence. Moreover, based 
on the EGFP levels, a similar efficiency of transfection could 
be used for cellular ABCG2 expression studies.
As documented in Fig. 1a, the ABCG2 protein expression 
in the HEK293 cells was examined by Western blotting. We 
found that the total expression levels of the K360Δ, F373C, 
T434M, and S476P ABCG2 variants were similar to that 
of the wild-type protein, the variants M71V, Q141K, and 
T153M had lower but well measurable expression, while the 
R147W and R383C variants showed no measurable expres-
sion in this system. As a well-studied mutant, the catalyti-
cally inactive K86M variant was also expressed in these 
studies, showing a low but well measurable expression level. 
Interestingly, in all cases when ABCG2 expression was well 
measurable, most of the transiently expressed protein was 
fully glycosylated.
In the experiments shown in Fig. 1b, the transiently trans-
fected HEK293 cells were labeled with 5D3 monoclonal 
antibody, which recognizes an extracellular epitope of the 
ABCG2 protein, thus indicating the amount of ABCG2 pre-
sent in the plasma membrane, as measured by flow cytom-
etry after EGFP gating (see “Materials and methods”). The 
results showed that two of the mutants, R147W and R383C 
(in accordance with the total ABCG2 levels), could not be 
found in the plasma membrane. The mutant ABCG2 variants 
M71V, Q141K, and F373C showed significantly lower mem-
brane expression levels than the wild type protein, while 
the plasma membrane expression of the T153M, K360Δ, 
T434M, and S476P variants was similar to the wild type.
Figure 1c demonstrates the transport activity measure-
ments of the ABCG2 variants transiently expressed in HEK 
cells. The measurement of the Hoechst dye extrusion is 
a very sensitive assay, and the relatively high level of the 
ABCG2 variants expressed transiently can provide a high 
transport activity (MAF) value [29]. Thus, even in the case 
of a lower membrane expression level, most of the stud-
ied protein variants showed an efficient dye extrusion. Still, 
there was no measurable dye transport activity in the case of 
the R147W and R383C mutants, similar to the K86M inac-
tive variant (or the empty vector, containing IRES-EGFP).
Figure 1d shows confocal microscopy images of the HEK 
cells transiently expressing the ABCG2 variants. While the 
Western blot or the surface expression values obtained by 
the 5D3 antibody binding data provide more quantitative 
data (see Fig. 1b), these images also indicate a correspond-
ing expression level and localization of the ABCG2 protein. 
Fig. 1  Transient expression and dye extrusion capacities of WT and 
mutant ABCG2 forms in HEK cells 48 h after transfection. a Western 
blot of transfected HEK cells. (Left panel: representative Western-
blot, right panel: densitometry results of four blots.) The R147W and 
R383C variants showed no measurable expression, and the K86M, 
M71V and Q141K variants showed significantly reduced expression. 
The T153M and F373C variants showed slightly lower expression 
than WT, while K360Δ, T434M and S476P were similar to WT. b 
Determination of cell surface expression of ABCG2 by 5D3 antibody 
labelling. We could not detect surface expression in the case of the 
R147W and R383C variants; M71V and F373C showed significantly 
lower cell surface expression than WT (four independent parallel 
experiments). c Measurement of Hoechst dye extrusion capacity. In 
case of the R147W and R383C variants we could measure similar, 
very low MDR activity factors than in the case of the non-functional 
mutant K86M, and the IRES-empty vectors. The Q141K, K360Δ 
T434M and S476P proteins showed somewhat lower activities than 
the WT ABCG2 (four independent parallel experiments). d Confocal 
images of HEK cells transiently expressing the ABCG2 variants. The 
variants which could be expressed all reached the plasma membrane. 
The scale bars represent 20 μm. Blue: DAPI, red: ABCG2. The stars 
indicate the results of t-tests; *p < 0.05, **p < 0.01, ***p < 0.001
◂
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These images show that the T153M, K360Δ, F373C, 
T434M, S476P variants localized—at least partly—in the 
plasma membrane, while the expression of the R147W and 
R383C variants was negligible.
Transient expression of the ABCG2 variants in Sf9 
insect cells
In the following experiments, we have transiently expressed 
the wild-type and the mutant ABCG2 variants in the Sf9 
insect cell–baculovirus system, and in Sf9 cell membrane 
preparations examined the expression levels and the activity 
of the protein variants (see Fig. 2).
As expected, in this system we could express all the 
ABCG2 protein variants at similar, high levels, and even 
the variants not expressed in the human cell lines (R147W 
and R383C) could be properly expressed (see Fig. 2a—it has 
been well documented that Sf9 cells can efficiently produce 
membrane proteins with folding or processing problems as 
well—[30]).
Figure  2b demonstrates the ABCG2 ATPase activ-
ity in this expression system. Basal, prazosin-stimulated, 
and quercetin-stimulated ABCG2-ATPase activities were 
measured in the isolated membrane vesicles. In these 
experiments, equal amounts of membrane proteins were 
added to the assay and the ABCG2-specific ATPase activity 
was determined by the addition of a selective ABCG2 inhibi-
tor, Ko143 (see “Materials and methods”). As documented, 
although showing similar membrane expression levels in 
the Sf9 cells, the R147W and R383C ABCG2 variants had 
neither basal nor drug-stimulated activities in these experi-
ments. The ABCG2-T153M, F373C, and S476P proteins 
had lower basal and/or stimulated ATPase activity, while 
the T434M variant, interestingly, showed higher basal and 
prazosin-stimulated activities. The activity of the ABCG2-
K360Δ protein was similar to the WT protein.
Stable expression of the ABCG2 variants in HeLa 
cells
To further examine the effects of these mutations, we have 
generated stable HeLa cell lines expressing the ABCG2 vari-
ants, by using the Sleeping Beauty transposon-transposase 
system (see “Materials and methods”). The transposon vec-
tor contained the ABCG2-IRES2-EGFP sequence inserted 
from the vector used in the transient expression studies. 
Thus, the stable cell lines expressed both the ABCG2 vari-
ants and EGFP from the same vector. In order to express 
the ABCG2 protein at a relatively uniform and low level, 
better representing the potential physiological expression 
levels than the transiently expressing HEK cells, the low 
EGFP-expressing HeLa cells were sorted out for these 
experiments. To examine the ABCG2 gene copy numbers 
in the low-expressing cells, a qPCR assay was performed 
in the gDNA isolates. The results shown in Suppl Fig. 1 
demonstrate that the vector was inserted only in low copy 
numbers in the stable cell lines, the ABCG2 copy numbers 
showing values between 1 and 3.
Figure 3a demonstrates Western blotting studies for the 
total protein expression of ABCG2 variants in stable HeLa 
cell lines. These results show similar expression levels of 
the K360Δ, T434M, and S476P ABCG2 variants to that of 
the WT protein. Somewhat lower expression was found for 
the ABCG2-T153M protein, and significantly lower stable 
expression levels were observed for the M71V, Q141K, and 
F373C variants. Practically no stable protein expression was 
seen for the R147W and R383C ABCG2 variants. These 
results show the potential for a more sensitive discrimination 
of the genetic variants in the stable ABCG2 expression sys-
tem than that observed in transient expression (see Fig. 1a).
In order to clarify the potential sources of the differences 
in protein expression of the ABCG2 variants in the stable 
HeLa cell lines, we have determined the respective mRNA 
levels in these cells. According to the qPCR studies, simi-
lar ABCG2 mRNA expression levels were found in all the 
stable cell lines expressing the ABCG2 variants (see Suppl. 
Figure 2). Thus, differences in the mRNA expression levels 
Fig. 2  ABCG2-ATPase activity measurements in isolated Sf9 cell 
membranes containing the ABCG2 variants. a Western-blot analysis 
of isolated membranes. All ABCG2 variants could be expressed in 
these cells at similar levels as the WT protein. b Basal, prazosin- and 
quercetin-stimulated ATPase activity measurements in cholesterol-
loaded Sf9 cell membranes. Although the R147W and R383C vari-
ants were expressed in the Sf9 cells, these variants did not show any 
ABCG2-ATPase activity. The T153M, F373C and S476P variants 
had lower basal and/or stimulated activities, while the T434M variant 
showed higher activity than the WT. The stars indicate the results of 
t-tests: *p < 0.05, **p < 0.01, ***p < 0.001 (at least three independ-
ent measurements with three parallels)
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Fig. 3  ABCG2 expression and dye extrusion capacity measurements 
in stable HeLa cell lines, expressing the ABCG2 variants. The cell 
lines were generated by a transposon-based system and selected to 
express low levels of the protein. a Western blot analysis of stable 
HeLa cells (left panel: representative Western-blot, right panel: densi-
tometry results of three blots). The ABCG2 M71V, Q141K, R147W, 
F373C and R383C variants showed low levels of ABCG2 proteins 
in these cells. b Membrane expression of the mutant proteins. The 
R147W and R383C variants did not reach the plasma membrane. 
We found lower plasma membrane expression levels in the case of 
the M71V, Q141K and F373C variants (four independent experi-
ments). c Hoechst dye extrusion was not measurable in the case of 
the R147W and R383C variants, while lower dye extrusion capac-
ity was observed in the case of the F373C and T434M variants (four 
independent experiments). d Representative confocal images of sta-
ble HeLa cells. Intracellular localization was observed for the R147W 
and R383C variants, while the other variants showed mainly plasma 
membrane expression. The scale bar represents 20 μm. Blue: DAPI, 
red: ABCG2. The stars indicate the results of t-tests; *p  <  0.05, 
**p < 0.01, ***p < 0.001
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may not cause the observed differences in the protein expres-
sion of the variants.
In the following experiments, shown in Fig. 3b, we meas-
ured the plasma membrane expression levels of the ABCG2 
variants in the low EGFP-expressing stable HeLa cells by 
5D3 antibody binding, using flow cytometry. These results 
closely corresponded to the total protein measurements, 
that is, high membrane expression levels (similar to the WT 
protein) were observed for the K360Δ, T434M, and S476P 
ABCG2 variants. In these experiments the ABCG2-T153M 
protein also had a similar cell surface expression. Signifi-
cantly lower membrane expression was found for the M71V, 
Q141K, and the F373C variants, while no membrane expres-
sion was observed for the R147W and R383C variants.
In Fig. 3c, we show the results for the Hoechst dye extru-
sion activity of the ABCG2 variants stably expressed in the 
HeLa cells. As documented, there was no ABCG2-depend-
ent transport activity in the stable cell lines expressing the 
R147W and R383C variants; lower transport activity was 
found for the F373C and T434M variants, while the Hoechst 
dye extrusion capacity was similar to the WT ABCG2 in 
cells expressing the M71V, Q141K, T153M, K360Δ, and 
S476P ABCG2 variants.
Confocal images from these stable HeLa cell lines 
(Fig. 3d) showed that the R147W and R383C variants 
localized exclusively intracellularly. Lower expression 
levels than the wild-type, and partial plasma membrane 
localization could be detected in the case of the M71V, 
Q141K, T153M variants. The K360Δ, F373C, T434M, 
and S476P variants showed similar high expression and 
membrane localization as the WT ABCG2 protein.
In the following experiments we have performed 
detailed, HyVolution 2 pseudo-super-resolution micros-
copy studies using the stable cell lines expressing ABCG2 
mutant variants showing impaired expression and localiza-
tion. In these studies, using specific organellar markers, 
we attempted to find the place of intracellular retention 
of these ABCG2 variants. As presented in Fig. 4a, we 
found that the wild-type ABCG2 protein was predomi-
nantly localized in the plasma membrane, with some Golgi 
staining. Most of the ABCG2-R147W and R383C variants, 
expressed at a low level, localized in the ER compartment. 
The poorly processed F373C variant was also predomi-
nantly localized in the ER, while partly in the Golgi and 
partly in the plasma membrane compartments. We found 
no significant co-localization of any of the immunostained 
ABCG2 variants with lysosomal markers.
In the following experiments, we have studied the effects 
of the selective and powerful proteasome inhibitor MG132 
on the expression of the ABCG2 variants in the stable cell 
lines. As shown in Fig. 4b, in the case of the WT protein, 
proteasome inhibition results in an increase in the expres-
sion of the fully glycosylated protein (upper band) and the 
appearance of the non-glycosylated ABCG2 (lower band). 
This indicates a partial degradation of both the glycosylated 
and the non-glycosylated WT protein in the proteasomes. 
In the control cells the fully glycosylated ABCG2-M71V 
mutant variant shows a much lower level of expression than 
the WT protein, while in the case of proteasome inhibition, 
most of this protein appears non-glycosylated. Interestingly, 
in the case of the ABCG2-R147W and R383C mutant vari-
ants there is practically no expression in the control cells, 
while a major non-glycosylated band appears when protea-
some activity is inhibited. This clearly coincides with the ER 
accumulation of these variants, seen in the co-localization 
studies (Fig. 4a).
Discussion
The ABCG2 multidrug transporter protein has several 
important roles in normal human tissues. In terms of locali-
zation, ABCG2 can be found mainly in the tissue interfaces 
(blood–brain barrier, placenta, liver, intestine), where this 
transporter performs the removal of numerous endogenous 
and exogenous harmful substances [1, 31]. Mutations or 
SNPs in the ABCG2 gene may influence the transport of 
these substrates, leading to pathological alterations in the 
human body. The reduced uric acid excretion by ABCG2 in 
the intestine leads to hyperuricemia and gout [11]. ABCG2 
also modulates the ADME-Tox properties of several drugs; 
thus an inadequate functioning of ABCG2 may dramatically 
change the side effects of these compounds [8].
ABCG2 has been reported to be present in several natu-
rally occurring variants in the human populations. Polymor-
phisms in the ABCG2 gene are frequent in Japan and in 
other Eastern countries [32–34], where the most studied var-
iants are the Q141K (MAF: 0.16–0.32), and Q126X (MAF: 
0.001), resulting in reduced-function or non-functional pro-
tein expression. In Caucasian populations, the Q126X vari-
ant has not been found, while, in addition to the frequently 
occurring Q141K variant (MAF: about 0.1), the R236X 
(truncated, non-functional variant) and the M71V, Q141K, 
R147W, T153M, K360Δ, F373C, R383C, T421A, T434M, 
and S476P ABCG2 variants were also reported to occur in 
several individuals [20, 22, 35, 36].
The most common variant, Q141K, has been described 
to increase the risk of hyperuricemia and gout; moreover, 
it has a significant effect on earlier onset of gout and was 
found to be associated with family history of the disease 
[36]. Recently it has been described that ABCG2 dysfunc-
tion is a strong independent risk factor for pediatric-onset 
hyperuricemia/gout [35].
It should be mentioned that the second most frequent 
variant of the ABCG2 is V12M. As we have previously 
reported, V12M does not alter the expression of the protein 
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in the red blood cell membranes of the carriers [19]. It has 
also been demonstrated that this variant does not affect 
the urate transport activity of the protein [34], while data 
from high-throughput studies [37, 38] and meta-analysis 
of several published results [36] indicated that this SNP 
may be in fact protective against gout.
In the present study we have performed a compre-
hensive, detailed study of naturally occurring ABCG2 
variants. A total of nine previously identified ABCG2 
Fig. 4  a HyVolution 2 pseudo-super-resolution images of HeLa cells 
stably expressing the wild-type ABCG2 and the R147W, F373C or 
R383C variants. Co-staining of ABCG2 (green) and the ER marker 
GRP78 (magenta) showed co-localization in the case of R147W and 
R383C, indicating that these variants are retained in the ER. Co-
staining of ABCG2 (green) and the Golgi marker Giantin (magenta) 
showed that the WT and F373C ABCG2 proteins partly localize in 
the Golgi system. Co-staining of ABCG2 (green) and a lysosome 
marker LAMP1 (magenta) showed only a low level of co-localization 
in all cases. The scale bars represent 5 μm in the merged and 1 μm 
in the enlarged pictures. b Western blot images of protein samples 
isolated from HeLa cells stably expressing WT, M71V, R147W and 
R383C variants. Non-treated (-) and 2  µM MG132-treated cells for 
24 hours (+) were examined. Western blot was performed according 
to the protocol described in the “Methods” section, using antibodies 
against ABCG2, actin and GFP (see Fig. 1)
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variants were tested—the M71V, Q141K, R147W, T153M, 
K360Δ, F373C, R383C, T434M, and S476P variants were 
expressed and analyzed in several assay systems. We have 
devised a suitable (EGFP corrected) transient mammalian 
cell expression systems for the evaluation of the ABCG2 
variants, allowing a relatively rapid and simple determina-
tion of both protein expression and function. We have also 
applied an Sf9 insect cell—baculovirus expression system, 
in which membrane protein expression is hardly affected 
by folding or trafficking problems, to directly study 
ABCG2 function. In addition, a transposon-based stable 
mammalian cell expression system, also correctable for 
EGFP expression, was applied to perform detailed stud-
ies on protein folding, trafficking, membrane localization, 
and transport activity. In these stable cell lines ABCG2 
and EGFP are expressed from the same vector and, as the 
cDNAs are separated by an IRES sequence, EGFP expres-
sion does not influence the expression of ABCG2. By sort-
ing out cells with low EGFP expression, we could generate 
stable HeLa cell lines with low inserted copies of ABCG2, 
closely corresponding to physiological ABCG2 expres-
sion. In addition to the present studies, these cell lines are 
useful for a detailed examination of the effects of various 
drugs, potentially modifying the expression, trafficking or 
function of the naturally occurring variants of ABCG2.
Based on the data presented in the results section, we 
conclude that the R147W and R383C ABCG2 protein 
variants are seriously damaged, practically not expressed 
in the mammalian cells. The high-resolution confocal 
microscopy results indicate that the small amounts of 
these ABCG2 variants do not reach the plasma membrane, 
are localized mainly in the ER, and thus have major fold-
ing problems. The M71V, Q141K, F373C, and T153M 
ABCG2 variants are expressed in variable amounts in the 
mammalian cells but are found only at low levels in the 
plasma membrane. As studied in detail, the F373C vari-
ant is mostly localized in the Golgi and other intracellu-
lar compartments, while we found no apparent accumu-
lation of any of the ABCG2 variants in the lysosomes. 
Previous studies have shown that the expression of the 
frequent ABCG2-Q141K variant is altered at several lev-
els—reduced mRNA maturation, protein folding, mem-
brane trafficking, and increased degradation of this protein 
have been suggested [24–27]. For the M71V variant our 
group demonstrated a reduced folding and trafficking in 
mammalian cells [21], while the partially defective F373C 
and T153M variants have not been studied as yet at the 
cellular level.
Since immunostaining does not recognize a partially 
degraded protein in the lysosomes, we have explored the 
effects of the selective proteasome inhibitor MG132 on the 
cellular fate of the ABCG2 variants (see Fig. 4b). We found 
that in the case of the WT protein, proteasome inhibition 
results in an increase in the expression of the fully glyco-
sylated protein, and the presence of a small amount of the 
non-glycosylated ABCG2, normally eliminated by the pro-
teasomes. In contrast, in the case of the ABCG2-R147W and 
R383C mutant variants, there is practically no expression 
of the fully glycosylated protein, while the appearance of a 
major non-glycosylated band when the proteasome activity 
is inhibited indicates that the misfolded, non-glycosylated 
protein (retained in the ER) is eliminated by the proteas-
omes. The ABCG2-M71V mutant variant shows lower 
expression than the WT protein, and proteasome inhibition 
results in the appearance of a large amount of the non-glyco-
sylated protein, indicating partial ER retention and proteaso-
mal degradation of this variant. These experiments indicate 
that the WT ABCG2 goes through a cellular processing 
with only a minor portion retained in the ER and degraded 
by the proteasomes, while the variants variably mis-folded 
are mostly retained in the ER and rapidly eliminated by the 
proteasomes.
An important finding in the present work is that the 
K360Δ, T434M, and S476P ABCG2 variants are prop-
erly expressed and functional in the plasma membrane and 
thus, in spite of being missense variants, may not cause any 
pathological alterations. In the case of the ABCG2-T434M 
protein, the Hoechst dye extrusion experiments showed simi-
lar or lower transport capacity, while in the ATPase experi-
ments, we measured a higher activity. These findings may 
indicate a slight functional and/or trafficking problem with 
this variant.
While this manuscript was under review, Toyoda et al. 
[23] reported an analysis of the variants R147W, T153M, 
K360Δ, F373C, T421A, T434M, S476P, S572R, D620N at 
the clinical level and performed a detailed cellular study 
using HEK cells, membrane vesicles, and a Xenopus oocyte 
expression system. The expression and localization of these 
variants, as reported in this paper, in most cases are in 
accordance with our current results and clearly establish the 
potential clinical role of the non-functional variants. Still, 
the approaches were somewhat different, e.g. our stable 
cell lines, expressing low levels of an untagged ABCG2, 
may be more informative regarding mild changes in expres-
sion and trafficking, as the GFP tag on the ABCG2 protein 
may alter these parameters (see in [21], Suppl. Figure 5). A 
potential result of these differences is that Toyoda et al. [23] 
concluded that the T434M and S476P variants (expressed 
with a GFP tag) did not have full activity in urate transport 
experiments. In contrast, we could not observe such differ-
ences in our transport and ATPase experiments with the 
untagged protein (using several well-established substrates 
of the ABCG2 protein, including Hoechst 33342, quercetin 
and prazosin).
In Fig. 5a, the positions of the studied amino acid vari-
ants are depicted in the recently published atomic level model 
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of the human ABCG2 protein [28]. The two non-expressing 
mutant variants (R147W and R383C), and two of the variants 
which showed lower expression (Q141K, F373C) are localized 
to the so-called connector region (see Fig. 5b). This region 
has been shown to be crucially important in the stabilization 
and the structural rearrangements during the ABCG2 transport 
cycle [26, 39], and an artificial mutation in the R383 position 
(R383A) was reported to damage the function and trafficking 
of this variant [40]. All these data further emphasize the key 
role of this region within the ABCG2 protein and predict a 
damaging effect of mutations in this region. As shown by us 
previously [21], the M71V variant, with reduced expression 
and trafficking, is localized in the NBD, and may directly alter 
the folding and maturation of the protein.
An interesting ABCG2 variant is the K360Δ protein, in 
which a lysine is deleted in a flexible intracellular loop, which 
is actually not seen in any of the atomic level models [28, 
41–43]. This lysine is close to other lysines (K357, K358), 
previously identified as ubiquitination sites of the ABCG2 
protein [44, 45]. The high expression of this variant in some 
of our experiments may suggest that the ubiquitin-mediated 
degradation of this variant is reduced.
In summary, the studies presented in this paper indicate 
that two naturally occurring ABCG2 variants, R147W and 
R383C, are detrimental to both expression and function, and 
thus heterozygous and especially homozygous or compound 
heterozygous patients carrying these ABCG2 variants may 
be especially susceptible to gout formation and drug toxicity, 
while less likely to have drug resistant tumors (in addition they 
may show a Junior-blood group feature—see [46]). Moreo-
ver, any potential treatment promoting the trafficking of these 
variants to the plasma membrane will not correct the defective 
function of these variants.
Individuals carrying the M71V, Q141K, T153M, and 
F373C ABCG2 variants, especially in a compound heterozy-
gous form, may have similar phenotypic and pathological fea-
tures, which is less efficient trafficking and function. In the 
case of these individual variants, a therapy promoting traf-
ficking to the plasma membrane may significantly improve 
ABCG2 function. The expression of T434M and S476P pro-
teins are not damaged; however, they may show somewhat 
altered transport function. In contrast, the ABCG2-K360Δ is 
a fully functional variant, with a potential of increased plasma 
membrane expression.
While the present experiments help to clarify the cellular 
phenotype of the specific ABCG2 variants examined, the tran-
sient expression system (yielding parallel ABCG2 and EGFP 
expression) used in this study provides a relatively simple and 
rapid screening tool. This system can be used for assessing the 
cellular expression, thus it allows to estimate potential medi-
cal effects (e.g. drug sensitivity or susceptibility to gout) in 
individuals carrying these mutations. The results presented 
here may also help to elucidate the specific role of the affected 
regions in the folding and functioning of the ABCG2 protein.
Materials and methods
Vector constructs
pIRES2-EGFP vector was a kind gift from László Nyi-
tray (ELTE Biochemistry Department). We have created 
Fig. 5  a Localization of the studied missense variants in the structure 
of the ABCG2 protein (based on Jackson et al. [28]). b The seriously 
damaged R147W, R383C variants and the Q141K, F373C variants—
which showed significantly lower expression and activity in our 
experiments—localize in the so-called connector area in the ABCG2 
structure (dark grey), demonstrating a key role of this region in the 
expression, maturation and activity of the ABCG2 protein. TMHs: 
transmembrane helixes, NBD: nucleotide-binding domain, ch: con-
nector/elbow helix
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the constructs containing the wild-type (WT), M71V, 
and Q141K ABCG2 variants in our previous work [21]. 
To generate the other mutant variants, two-step PCR 
mutagenesis was performed, using the WT ABCG2-con-
taining pIRES2 vector template amplified by primer pairs 
containing the desired mutation (see Suppl. Figure 3a). 
The ABCG2-IRES2-EGFP cassette was inserted in the 
pIRES2-EGFP vector after digestion by BamHI and NheI 
enzymes (for vector map see Suppl. Figure 4a).
The original transposon-transposase vectors were gen-
erated previously by Tamas Orban’s group (see [47], cor-
rection: [48]). The mutant variants of the ABCG2-IRES2-
EGFP cassette were inserted between IR-DRs in the 
transposon vector by using the NheI and AgeI enzymes, 
after PCR amplification with a backbone-specific reverse 
and an overhang forward primer that contained the desired 
AgeI cleavage sequence (see Suppl. Figures 3b, 4b). In 
addition to the mutant ABCG2 variant-containing vectors, 
we have generated a vector with the IRES2-EGFP cas-
sette without the ABCG2 sequence, to serve as a control 
in these experiments.
For Sf9-baculovirus expression studies we cloned the 
mutant versions of ABCG2 cDNA from pIRES2 vectors 
with NotI/SacI into the pAcUW-21-L plasmid (vector was 
a gift from Csilla Laczka-Ozvegy) after PCR amplification 
with primers containing restriction enzyme cutting site 
overhang (see Suppl. Figure 3c).
Mammalian cell culture, transfection, and MG132 
treatment
HEK293H and HeLa cells were grown in DMEM/high 
glucose/GlutaMAX medium (Gibco, cat. 10569010) com-
pleted with 10% FBS (Gibco, cat. 1640071) and 1% peni-
cillin–streptomycin (Gibco, cat. 15070063) at 37 °C (5% 
 CO2). Transient transfection of HEK293 cells was carried 
out with lipofectamine 2000 (Invitrogen, cat. 11668019) 
in Opti-MEM medium (Gibco, cat. 31985070), according 
to the manufacturer’s protocol. Protein determination and 
Hoechst dye extrusion measurements were carried out 48 h 
after transfection. MG132 treatment was performed by cul-
turing the cells for 24 h with 2 µM final MG132 concentra-
tion in DMEM/high glucose/GlutaMAX medium. We used 
a 10 mM MG132 in DMSO stock solution (Sigma-Aldrich, 
cat. M7449) and an equal volume of DMSO was added to 
the medium in the case of the non-MG132-treated control 
cells.
Generation of stable cell lines
The ABCG2-expressing stable cell lines were generated 
using the Sleeping Beauty transposon-transposase system. 
We used a 1:10 transposase coding plasmid: transposon 
plasmid ratio for transfection. HeLa cells were transfected 
with the mixed plasmids using Lipofectamine 2000 (Invitro-
gen, cat. 11668019) in Opti-MEM (Gibco, cat. 31985070). 
Three days after transfection, the EGFP positive cells were 
sorted using BD FACS Aria II and seeded on 6-well plates. 
After two more weeks of culturing, two cell populations 
were detected among the EGFP positive cells: a population 
with lower and one with higher EGFP fluorescence. The 
two separable populations were present, regardless of which 
mutant variant of ABCG2 they expressed. The low EGFP-
expressing cells were sorted and seeded on 6-well plates. 
Our further experiments were performed using these low 
EGFP-expressing stable cell lines.
gDNA isolation and copy number determination
Genomic DNA was isolated from stable cell lines with Gen-
tra Puregene Blood Kit (Qiagen), according to the manu-
facturer’s protocol for mammalian cell lines. Copy numbers 
were determined by TaqMan based qPCR as described pre-
viously ([47], corr.: [48]). Briefly, the qPCR probes were 
designed to recognize the left arm (IR-DR) of the integrated 
Sleeping Beauty cassette. For control copy number determi-
nation the RPPH1 gene was used.
Hoechst 33342 uptake measurements
Hoechst 33342 (Hst, Thermo Fisher, cat. H1399) uptake was 
determined either in transiently transfected HEK293 cells 
(with pIRES2 vectors, Suppl. Figure 4a) 48 h after transfec-
tion, or in the stable HeLa cell lines. Cells were trypsinized 
and then preincubated for 5 min at 37 °C with or without 
the selective ABCG2 inhibitor, Ko143 (2 µM). Measure-
ments were carried out in FACS Canto II, with continuous 
sampling for 80 s (linear phase of the uptake). The EGFP-
positive cells were gated at 20-s intervals. Initial slopes were 
calculated from these five points (0–80 s) by linear fitting 
(according to [21]). MAF (MDR activity factor) values were 
calculated as described previously [29].
Plasma membrane expression studies, flow 
cytometry
We determined the cell surface expression of ABCG2 in the 
stable HeLa cell lines and in transiently transfected HEK293 
cells 48 h after transfection. Antibody labeling was per-
formed in trypsinized cells with the ABCG2-specific 5D3 
mouse monoclonal antibody (gift of Bryan Sorrentino, Divi-
sion of Experimental Hematology, Department of Hema-
tology/Oncology, St. Jude Children’s Research Hospital). 
Ko143 is an ABCG2 inhibitor that has an impact on ABCG2 
conformation, thus helping 5D3 antibody recognition. 1 µM 
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Ko143 (Sigma-Aldrich, cat. K2144) was added to the sam-
ples before the measurements. Alexa Fluor 647-labeled 
IgG2b (Thermo Fisher, cat. A-21242) was used as a second-
ary antibody. Propidium iodide (final concentration: 1.6 µg/
ml, Sigma Aldrich, cat. 4170) was used for dead cell separa-
tion. Measurements were carried out in FACS Canto II after 
gating for live, EGFP positive cells.
Western blotting
Total protein from the cells was extracted by the addition 
of TE sample buffer (0.1 M TRIS-PO4, 4% SDS, 4 mM Na-
EDTA, 40% glycerol, 0.04% bromophenol blue, and 0.04% 
β-mercaptoethanol; materials from Sigma-Aldrich). Equal 
amounts of the protein samples were loaded on 10% acryla-
mide gels. Blots were probed with the following primary 
antibodies: anti-ABCG2 (BXP-21, Abcam, cat. ab3380), 
anti-EGFP (Abcam, cat. ab290), and anti-β-actin (Sigma, 
cat. A1978). Goat anti-mouse IgG (H + L) HRP conjugate 
(Abcam, cat. ab97023) and goat anti-rabbit IgG (H + L) HRP 
conjugate (Abcam, cat. ab6721) secondary antibodies were 
used to visualize and quantify the results. Detection was 
performed with Clarity Western ECL Substrate (BioRad, 
cat. 1705060) and luminography. Densitometric analysis was 
performed by ImageJ software v1.42q.
Immunostaining
HEK cells were seeded onto 8-well Nunc Lab-Tek II cham-
bered (Thermo Fisher, cat. 155409) at 5 × 104 cells/well den-
sity and grown for 48 h after transfection. Stably expressing 
HeLa cells were seeded onto ibiTreat µ-Slide 8 Well (Ibidi, 
cat. 80826) at 2 × 104 cells/well density and grown for 24 h. 
The samples were gently washed with Dulbecco’s modified 
phosphate-buffered saline (DPBS) and then fixed with 4% 
paraformaldehyde in DPBS for 10 min at room temperature. 
After several washing steps, the cells were blocked for 1 h 
at room temperature in DPBS containing 2% bovine serum 
albumin, 1% fish gelatin, 0.1% Triton-X 100, and 5% goat 
serum (blocking buffer). The samples were then incubated 
for overnight at 4 °C with the primary antibody (Bxp-21, 
1:200, Abcam, cat. ab3380) diluted in blocking buffer. 
After washing with DPBS, the cells were incubated for 1 h 
at room temperature with the secondary antibody (Alexa 
Fluor 647-conjugated goat anti-mouse, Thermo Fisher, cat. 
A-21235) diluted 1:250 in blocking buffer. Nuclei were 
stained with DAPI (1 µM final concentration). Cells were 
examined with Zeiss LSM 5710 laser scanning fluorescence 
confocal microscope (40 ×, oil immersion objective), and 
images were processed with ZEN 2012 software.
Immunostaining for pseudo‑super‑resolution 
microscopy
The four selected stably expressing HeLa cells (variants WT, 
R147W, R383C, F373C) were seeded onto ibiTreat µ-Slide 
8 Well (Ibidi, cat. 80826) at 2 × 104 cells/well density and 
grown for 24 h. The samples were gently washed with Dul-
becco’s modified phosphate-buffered saline (DPBS) and 
then fixed with 4% paraformaldehyde in DPBS for 15 min 
at room temperature. After several washing steps, the cells 
were blocked for 1 h at room temperature in DPBS con-
taining 2% bovine serum albumin, 1% fish gelatin, 0.1% 
Triton-X 100, and 5% goat serum (blocking buffer). The 
samples were then incubated for overnight at 4 °C with the 
primary antibodies (Bxp-21, 1:200, Abcam, cat. ab3380; 
Anti-GRP78, 1:500, Abcam, cat. ab21685; Anti-Giantin, 
1:1000, BioLegend cat. 924302; Anti-LAMP1, 1:250 Anti-
bodyGenie cat. CAB2582) diluted in blocking buffer. After 
washing with DPBS, the cells were incubated for 1 h at room 
temperature with the secondary antibodies (Alexa Fluor 568 
conjugated goat anti-mouse, Thermo Fisher, cat. A-11004; 
Alexa Fluor 647-conjugated goat anti-rabbit, Thermo Fisher, 
cat. A-21244), diluted 1:250 in blocking buffer. The sam-
ples were examined with Leica HyVolution 2 pseudo-super-
resolution imaging method, using a Leica TCS SP8 STED 
microscope equipped with a Leica HC PL APO 100 × STED 
white (1.4 NA) objective. The Alexa Fluor 568 and 647 dyes 
were excited with 552 and 638 nm laser, respectively. The 
fluorescence of each dye was detected sequentially and spec-
trally by a hybrid detector at 590–630 nm and 650–700 nm 
wavelengths, respectively. The pinhole diameter was set to 
0.6 AU in each channel. Huygens Pro deconvolution soft-
ware was used for image restoration and Leica LAS X 3.1.1 
software was used for image analysis.
Expression in Sf9 cells, membrane preparation, 
ATPase measurements
Sf9 insect cells were grown in suspension at 27 °C in TNM-
FH medium (Sigma-Aldrich, cat. T3285) supplemented with 
5% FBS. The cells were transfected with flashback ULTRA 
Kit (Oxford Expression Technologies Ltd.) according to the 
manufacturer’s protocol. Membrane expression studies were 
carried out as described previously [49].
ATPase activity of WT ABCG2 and the mutant vari-
ants was measured by colorimetric detection of inorganic 
phosphate liberation in microplates, as described previously 
[50, 51]. Protein concentrations (5 μg/well) were normalized 
according to Western blots for ABCG2; thus equal amounts 
of the ABCG2 variants were used in the measurements. Cho-
lesterol loading of the membranes was achieved by the addi-
tion of 0.6 mM RAMEB-cholesterol (Cyclolab Ltd, Buda-
pest, Hungary) before measurements, and the membranes 
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incubated for 10 min on ice, according to Telbisz et al. [49]. 
The measurement of the ATPase activity was started with 
the addition of 3.1 mM MgATP, the samples incubated at 
37 °C, and the reaction terminated after 25 min with the 
P-reagent [51]. Photometric measurements were carried out 
in Victor Multilabel plate reader (PerkinElmer) at 660 nm. 
ABCG2-specific ATPase reaction was verified by adding 
the ABCG2-specific inhibitor Ko143 to the reaction. We 
used the following concentration of ABCG2 inhibitors and 
substrates: vanadate 1 mM, Ko143 1 μM, quercetin 5 μM, 
prazosin 20 μM.
mRNA level measurements
mRNA was purified from the stable, ABCG2-expressing 
HeLa cells with PureLink MiniKit (Thermo Fisher Sci-
entific, cat. 12183018A) according to the manufacturer’s 
instructions. After cDNA conversion (Thermo Fisher Sci-
entific, High capacity cDNA reverse transcription kit, cat. 
4368814) mRNA levels were determined with qPCR probes 
against ABCG2 (Thermo Fisher Scientific, cat. 00184979) 
and RPLP0 (cat. 99999902), with TaqMan Universal Master 
Mix (Thermo Fisher Scientific, cat. 4304437) according to 
the manufacturer’s protocol. Reactions were run on a StepO-
nePlus™ platform (Thermo Fisher Scientific), and ABCG2 
mRNA levels were normalized with ΔΔCt method to RPLP0 
mRNA levels.
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